SM
GBT

SG3 Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

SG3 Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30,000
Closed -$878K – 1493
2021
Q4 		$878K Buy
+30,000
New +$929K 0.02% 511
2020
Q3 		– Sell
-47,000
Closed -$2.97M – 1123
2020
Q2 		$2.97M Buy
+47,000
New +$3.22M 0.21% 130

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SG3 Management's GBT Position: Q1 2022 in Review

SG3 Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2022, closing a stake of 5,000 shares — an estimated $146K sold.

SG3 Management first reported a position in GBT in Q4 2020 and held it in 2 quarters. The position peaked at $346K in Q4 2020. 204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

  • SG3 Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 5,000 Global Blood Therapeutics, Inc. shares in Q1 2022, an estimated $146K.
  • SG3 Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 2 quarters.
  • SG3 Management's Global Blood Therapeutics, Inc. position peaked at $346K in Q4 2020.
  • 204 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.